Navigation Links
Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
Date:5/23/2011

RICHMOND, Calif., May 23, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).  The meeting was held in Seattle from May 18-21, 2011.

"Sangamo's ZFP technology is revolutionizing cell and gene therapies," stated Barrie Carter, Ph.D., a member of Sangamo's scientific advisory board and President of ASGCT for 2010-2011. "ZFP Nuclease (ZFN) technology provides an efficient and precise process for editing any DNA sequence in a cell, making development of therapeutic gene-editing applications a reality.  Sangamo has ongoing human clinical trials to evaluate ZFN-based therapeutics in HIV/AIDS and ZFP transcription factors (ZFP TFs) in neuroregeneration. As this technology functions at the DNA level, it can be applied to numerous diseases and any disease-related gene."

ASGCT meeting presentations included previously described preliminary clinical data from Sangamo's ongoing Phase 1 clinical trial in HIV/AIDS (SB-728-902) as well as data from preclinical and research-stage human therapeutic programs.  Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and monogenic diseases such as hemophilia, ADA-SCID, retinal neurodegeneration and epidermolysis bullosa.  Positive preclinical data were also presented from studies of Sangamo's ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of stroke.

"These data presentations illustrate the broad range of potential applications for ZFP Therapeutics including monogenic diseases, infectious diseases and neuroregeneration, as well as new approaches to tissue engineering and stem cell modifications," said Edward Lanphier, Sangamo's president and CEO. "Using our ZFP technology we can modify and regulate genes with singular specificity and high efficiency. Importantly, we can directly modify genes, correcting inherited mutations and restoring function while preserving the gene's natural regulation. These presentations demonstrate the rapid progress that Sangamo scientists and our collaborators have made in the development of our ZFP technology platform for the generation of novel therapeutic approaches for the treatment of unmet medical needs."

ASGCT Highlights

  • Sangamo scientist, Michael Holmes, Ph.D.,was a selected speaker at this year's Presidential Symposium and gave a presentation entitled "In vivo Delivery of Zinc Finger Nucleases Mediates Genome Editing to Correct Genetic Disease." (Abst# 49). Additional presentations covered ZFN-mediated gene editing approaches for monogenic diseases (Abst# 26, 93, 268, 423, 498, 631, 633, 648 and 689).
  • Sangamo's collaborator, Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California was invited to chair the session, "Emerging Field Review: HIV Gene Therapy," in which Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine also presented.
  • Several presentations highlighted Sangamo's extensive HIV program, including clinical data from Sangamo's SB-728-T program (Abst# 598), preclinical data from Sangamo's program to disrupt the CCR5 gene in hematopoietic stem cells (Abst# 314 and 99) and positive preclinical data demonstrating ZFN-mediated disruption of  another co-receptor for HIV infection, CXCR4 (Abst# 484).

All abstracts for the meeting are available online at http://www.asgct.org/am11/index.php.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy.  Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics and therapeutic applications of Sangamo's ZFP technology platform to specific human diseases and unmet medical needs, including monogenic diseases, neuroregeneration and stem cell applications. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to whether clinical trials will validate and support tolerability and efficacy of ZFP Therapeutic approaches, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
2. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
3. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
4. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
5. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
11. Sangamo Announces Closing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... IRVINE, Calif. , March 27, 2017  Cryoport, ... announced that it intends to offer shares of common ... shelf registration statement on file with the Securities and ... market and other conditions, and there can be no ... be completed, or as to the actual size or ...
(Date:3/27/2017)... MELVILLE, N.Y. , March 27, 2017 To ... U.S.A. , Inc., a leader in digital imaging ... Vision Expo East convention, held at New York,s ... 2, 2017. Save Your Vision Month, sponsored by the American ... health and the importance of receiving comprehensive eye exams. In ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... organization of nurses and supply chain professionals, will hold their first Northeast Regional ... Analysis in Bundles.” , “Increasingly, supply chain and value analysis professionals have ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... Schwerzenbach, Switzerland (PRWEB) , ... March 27, 2017 ... ... the food industry. Conventional sodium testing methods are complicated and require expert user ... presents a new analytical method dedicated to the simplified, yet highly accurate, determination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... settlement agreement to resolve the pending litigation between itself and 1800 Vending DBA ... of Utah). , “I am thrilled to announce that we have now reached ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
Breaking Medicine News(10 mins):